Brian Hill, MD, PhD

Dr. Hill is the Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute. He received his undergraduate degree from Dartmouth College and earned his Ph.D. in genetics through work done at Cold Spring Harbor Laboratory. He received his medical degree from the University of Chicago Pritzker School of Medicine where he also completed his residency in Internal Medicine. He conducted his hematology/oncology fellowship at the Cleveland Clinic where he is now a Staff Physician. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma. He is the principal investigator of multiple on-going clinical trials of developmental therapeutics including novel cellular therapies. He serves as the Chairman of the Pharmacy & Therapeutics (P&T) Committee within the Department of Hematology and Medical Oncology, Co-Director of the Lymphoid Malignancies Center of Excellence and serves on the editorial board of several peer reviewed journals. He is Associate Professor of Medicine of the Cleveland Clinic Lerner College of Medicine is an active member of the Case Comprehensive Cancer Center, American Society of Hematology (ASH), cooperative groups of the National Cancer Institute (NCI), the Center for International Blood and Marrow Transplant Research (CIBMTR) as well as a committee member of the National Comprehensive Cancer Network (NCCN) CLL panel. He also serves on the content advisory panel for the Follicular Lymphoma Foundation and on the scientific advisory board of the CLL Society.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GenentechDate added:03/14/2023Date updated:03/14/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbbvieDate added:03/14/2023Date updated:03/14/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GenmabDate added:03/14/2023Date updated:03/14/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PharmacyclicsDate added:03/14/2023Date updated:03/14/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaDate added:03/14/2023Date updated:03/14/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BeigeneDate added:03/14/2023Date updated:03/14/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GileadDate added:03/14/2023Date updated:03/14/2023